Rising Hypertension Rates Fuel The Growth Of ACE Inhibitors Market: A Key Catalyst Accelerating ACE Inhibitors Market Growth in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

ACE Inhibitors Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size for ACE inhibitors has seen consistent growth in the past few years. Its value is expected to increase from $7.15 billion in 2024 to $7.41 billion in 2025, indicating a compound annual growth rate (CAGR) of 3.6%. The growth observed during the historical period can be credited to factors such as a rise in cases of cardiovascular disease, growing elderly population, clinical efficacy and safety record, high frequency of diabetes, as well as regulatory approvals and guidelines.

ACE Inhibitors Market Size Forecast: What's the Projected Valuation by 2029?
We predict a strong expansion in the ACE inhibitors market size in the upcoming years, with an anticipated worth of $9.42 billion in 2029 and a compound annual growth rate (CAGR) of 6.2%. Factors contributing to this growth during the forecast period include an increasing worldwide frequency of cardiovascular diseases, wider guidelines for hypertension treatment, advances in combined therapies, an emphasis on managing heart failure, and increased general awareness and access to healare. Noteworthy trends for the forecast period encompass a concentration on kidney protection, the favored use of renin-angiotensin system inhibitors, competition on generic medication and price pressure, a patient-focused approach in the healare industry, and updates in regulation and safety concerns.

View the full report here:
https://www.thebusinessresearchcompany.com/report/ace-inhibitors-global-market-report

What Are the Drivers Transforming the ACE Inhibitors Market?
The growing occurrence of hypertension-related disorders is anticipated to fuel the expansion of the ACE inhibitors market. Hypertension or high blood pressure, manifests as unusually high pressure in the blood vessels. ACE inhibitors, which stand for angiotensin-converting enzyme inhibitors, are a category of drugs used in managing and treating hypertension. These drugs work by helping blood vessels relax, which lowers blood pressure and improves blood flow. As stated by the World Health Organization, in March 2023, a specialized agency of the United Nations based in Switzerland, it was revealed that approximately 1.28 billion adults aged between 30 and 79 globally suffered from hypertension. The majority of this population, about two-thirds, live in low- to middle-income countries. Over the past 30 years, an additional 650 million people in the age range of 30-79 have developed hypertension. Approximately 46% of adults with hypertension are believed to be undiagnosed and therefore, unaware of their condition. The last 3 decades have seen a rise in the number of adults aged 30-79 with hypertension by 650 million. Approximately 46% of individuals affected by hypertension presumably remain undiagnosed and hence, ignorant of their condition. Consequently, the escalating frequency of hypertension disorders is steering the growth of the ACE inhibitors market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10671&type=smp

Which Emerging Trends Are Transforming the ACE Inhibitors Market in 2025?
In the ACE inhibitors market, a primary trend that is gaining traction is the stimulation of product innovation. Leading firms in this sector are emphasizing the creation of novel products in an attempt to consolidate their standing and gain a competitive edge. For instance, Travere Therapeutics, a US-based biopharma firm, acquired FDA approval for FILSPARI (sparsentan) in February 2023, introducing a groundbreaking non-immunosuppressive therapy for patients with IgA nephropathy (IgAN). The therapeutic options included systemic glucocorticoids, angiotensin-converting enzyme (ACE) inhibitors, and medication for hypertension, such as angiotensin-receptor blockers (ARBs). It is the only approved non-immunosuppressive treatment, a once-daily oral drug tailored to manage adults with primary IgAN who are at risk of rapid disease progression, usually having a UPCR below 1.5 g/g and proteinuria.

Which Segments in the ACE Inhibitors Market Offer the Most Profit Potential?
The ace inhibitors market covered in this report is segmented -

1) By Type: Sulfhydryl-containing Agents, Dicarboxylate-containing Agents, Phosphonate-containing Agents
2) By Drug: Ramipril, Enalapril, Benazepril, Fosinopril, Captopril, Moexipril, Other Drugs
3) By Dosage Form: Oral Tablets, Oral Solutions
4) By Application: Heart Failure, Chronic Kidney Disease, Hypertension, Diabetes, Heart Attack, Other Applications
5) By End-Users: Hospitals, Online Drug Stores, Other End-Users

Subsegments:
1) By Sulfhydryl-Containing Agents: Captopril, Zofenopril
2) By Dicarboxylate-Containing Agents: Enalapril, Lisinopril, Ramipril, Quinapril, Benazepril, Perindopril
3) By Phosphonate-Containing Agents: Fosinopril

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=10671&type=smp

Which Firms Dominate the ACE Inhibitors Market by Market Share and Revenue in 2025?
Major companies operating in the ACE inhibitors market include Pfizer Inc., Novartis AG, Johnson & Johnson Private Limited, Merck KGaA, Sanofi S.A., Bayer AG, Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Co., Takeda Pharmaceuticals Company, Daiichi Sankyo Company Ltd., UCB Schwarz Pharma Inc., Endo International plc, Sun Pharmaceutical Industries Ltd., Boehringer Ingelheim, Bausch Health Companies Inc., Dr. Reddy's Laboratories, Abbott Laboratories, Eli Lilly and Company, Cipla Limited, GlaxoSmithKline plc, Cadila Healare Limited, AbbVie Inc., Sandoz Group AG, Accord Healare Ltd., AstraZeneca plc, Lupin Limited, Macleods Pharmaceuticals Limited, Zydus lifescience Ltd., Apotex Inc.

Which Regions Offer the Highest Growth Potential in the ACE Inhibitors Market?
North America was the largest region in the ACE inhibitors market in 2024.Asia-Pacific is expected to be the fastest-growing region in the global ACE inhibitors market report during the forecast period. The regions covered in the ace inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10671

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Speak With Our Expert:
Saumya Sahay
Europe - +44 7882 955267,
Asia: +91 88972 63534,
Americas - +1 310-496-7795 or
Email:saumyas@tbrc.info
Follow Us On:
• LinkedIn: https://in.linkedin.com/company/the-business-research-company

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.